Iranian Journal of Pathology

Differences in CD24 Expression Between Prostate Adenocarcinoma and Benign Prostatic Hyperplasia: A Cross-sectional Study

Document Type : Original Research

Authors

Mahdi Sajedifar 1
Atieh Jafarabadi 1
Mohammadreza Jalali Nadoushan 2

1 Student Research Committee, Faculty of Medicine, Shahed University, Tehran, Iran

2 Department of Pathology, Faculty of Medicine, Shahed University, Tehran, Iran

https://doi.org/10.30699/ijp.2024.2021959.3251
Abstract
Background & Objective: CD24 is a small, highly glycosylated membrane protein whose expression is associated with tumorigenesis and the progression of several types of cancer. Prostate adenocarcinoma is one of the most common cancers in men, and microscopic Gleason grading is an important factor affecting prognosis. This study aims to investigate the relationship between immunohistochemical expression of CD24 and its relationship with benign prostatic hyperplasia (BPH) and Gleason grade in prostate adenocarcinoma.
Methods: This cross-sectional study was conducted on 163 patients, with an average age of 70.63±9.05 years, including 78 (47.9%) patients with prostate adenocarcinoma and 85 (52.1%) patients with benign prostatic hyperplasia., referred to Mostafa Khomeini Hospital in Tehran between 2018 and 2021, who underwent open prostatectomy or Trans Urethral Resection of Prostate (TURP). Immunohistochemical staining was used to evaluate CD24 expression, and Gleason grade was determined in the case of prostate adenocarcinoma. Data were analyzed with SPSS 22 and a P-value<0.05 was considered statistically significant.
Results: The percentage and intensity of CD24 staining in prostate adenocarcinoma patients was significantly higher than in BPH patients (P<0.05). Gleason score strongly correlated with the percentage and intensity of CD24 staining (P<0.05). The immunoreactive score, obtained by multiplying the CD24 expression percentage with staining intensity, was also significantly related to the Gleason score (P<0.05).
Conclusion: CD24 expression can be considered as a factor in differentiating cases of prostate adenocarcinoma from benign prostatic hyperplasia. Also, a high level of this marker can indicate the progress of prostate cancer.

Keywords

CD24
prostate adenocarcinoma
Gleason grade
BPH

Subjects

  1.  

    1. Zhao J, Xia K, He P, Wei G, Zhou X, Zhang X. Recent advances of nucleic acid-based cancer biomarkers and biosensors. Coord Chem Rev. 2023;497:215456. [DOI:10.1016/j.ccr.2023.215456]
    2. Cary KC, Cooperberg MR. Biomarkers in prostate cancer surveillance and screening: past, present, and future. Ther Adv Urol. 2013;5 (6):318-29. [DOI:10.1177/1756287213495915] [PMID] []
    3. Lesko LJ, Atkinson Jr A. Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: criteria, validation, strategies. Ann Rev Pharmacol Toxicol. 2001;41 (1):347-66. [DOI:10.1146/annurev.pharmtox.41.1.347] [PMID]
    4. Tonry C, Finn S, Armstrong J, Pennington SR. Clinical proteomics for prostate cancer: understanding prostate cancer pathology and protein biomarkers for improved disease management. Clin Proteom. 2020;17 (1):1-31. [DOI:10.1186/s12014-020-09305-7] [PMID]
    5. Doultsinos D, Mills IG. Derivation and application of molecular signatures to prostate cancer: opportunities and challenges. Cancers. 2021;13 (3):495. [DOI:10.3390/cancers13030495] [PMID]
    6. McGrath S, Christidis D, Perera M, Hong SK, Manning T, Vela I, et al. Prostate cancer biomarkers: Are we hitting the mark? Prostate Int. 2016;4 (4):130-5. [DOI:10.1016/j.prnil.2016.07.002] [PMID]
    7. Bolton DM, Papa N, Ta AD, Millar J, Davidson AJ, Pedersen J, et al. Predictors of prostate cancer specific mortality after radical prostatectomy: 10 year oncologic outcomes from the Victorian Radical Prostatectomy Registry. BJU Int. 2015;116:66-72. [DOI:10.1111/bju.13112] [PMID]
    8. Ortner G, Tzanaki E, Rai BP, Nagele U, Tokas T. Transperineal prostate biopsy: the modern gold standard to prostate cancer diagnosis. Turk J Urol. 2021;47 (Suppl 1):S19. [PMID] [DOI:10.5152/tud.2020.20358]
    9. Matuszczak M, Schalken JA, Salagierski M. Prostate cancer liquid biopsy biomarkers' clinical utility in diagnosis and prognosis. Cancers. 2021;13 (13):3373. [PMID] [DOI:10.3390/cancers13133373]
    10. Schabath H, Runz S, Joumaa S, Altevogt P. CD24 affects CXCR4 function in pre-B lymphocytes and breast carcinoma cells. J Cell Sci. 2006;119 (2):314-25. [DOI:10.1242/jcs.02741] [PMID]
    11. Lim S-C, Oh S-H. The role of CD24 in various human epithelial neoplasias. Pathol Res Pract. 2005;201 (7):479-86. [DOI:10.1016/j.prp.2005.05.004] [PMID]
    12. Zheng Z, Shao N, Weng H, Li W, Zhang J, Zhang L, et al. Correlation between epidermal growth factor receptor and tumor stem cell markers CD44/CD24 and their relationship with prognosis in breast invasive ductal carcinoma. Med Oncol. 2015;32:1-11. [DOI:10.1007/s12032-014-0275-2] [PMID]
    13. Fang X, Zheng P, Tang J, Liu Y. CD24: from A to Z. Cellular Molecul Immunol. 2010;7 (2):100-3. [DOI:10.1038/cmi.2009.119] [PMID]
    14. Liu C, Zhang Y, Gao J, Zhang Q, Sun L, Ma Q, et al. A highly potent small-molecule antagonist of exportin-1 selectively eliminates CD44+ CD24-enriched breast cancer stem-like cells. Drug Resist Updat. 2023;66:100903. [DOI:10.1016/j.drup.2022.100903] [PMID]
    15. Wang Y, Yu H, Yu M, Liu H, Zhang B, Wang Y, et al. CD24 blockade as a novel strategy for cancer treatment. Int Immunopharmacol. 2023;121:110557. [DOI:10.1016/j.intimp.2023.110557] [PMID]
    16. Kwon MJ, Han J, Seo JH, Song K, Jeong HM, Choi J-S, et al. CD24 overexpression is associated with poor prognosis in luminal A and triple-negative breast cancer. PLoS One. 2015;10 (10):e0139112. [DOI:10.1371/journal.pone.0139112] [PMID]
    17. Borziak K, Finkelstein J, editors. Gene Expression Markers of Prognostic Importance for Prostate Cancer Risk in Patients with Benign Prostate Hyperplasia. 2022 44th Annual International Conference of the IEEE Engineering in Medicine & Biology Society (EMBC); 2022: IEEE. [DOI:10.1109/EMBC48229.2022.9871422]
    18. Chen Q, Huang Z, Zhang W, Zheng Z, Sun A. Expression of CD24 in prostate cancer tissues and its clinical significance. Chin J Cancer Biother. 2019:1383-6.
    19. Cui X, Wang S, Wang L. CD24 mutant p53 contribute to racial disparities in prostate cancer. Cancer Research. 2021;81 (13_Supplement):778-. [DOI:10.1158/1538-7445.AM2021-778]
    20. Weichert W, Denkert C, Burkhardt M, Gansukh T, Bellach J, Altevogt P, et al. Cytoplasmic CD24 expression in colorectal cancer independently correlates with shortened patient survival. Clin Cancer Res. 2005;11 (18):6574-81. [DOI:10.1158/1078-0432.CCR-05-0606] [PMID]
    21. Karimi-Busheri F, Rasouli-Nia A, Zadorozhny V, Fakhrai H. CD24+/CD38-as new prognostic marker for non-small cell lung cancer. Multidiscip Respir Med. 2013;8:1-9. [DOI:10.4081/mrm.2013.577]
    22. Liu C, Zheng S, Shen H, Xu K, Chen J, Li H, et al. Clinical significance of CD24 as a predictor of bladder cancer recurrence. Oncol Lett. 2013;6 (1):96-100. [DOI:10.3892/ol.2013.1357] [PMID]
Iranian Journal of Pathology
Volume 19, Issue 3
Summer 2024
Pages 306-310

  • Receive Date 01 December 2023
  • Revise Date 02 February 2024
  • Accept Date 22 April 2024

Home

Guide for Authors

Submit Manuscript

Contact Us